Scientific Programme

   Scientific Programme DOWNLOAD

* Publishing Date: October 19, 2021

Thursday, February 3, 2022

Opening Talk                                 

Time Presentation Title Speaker
08:30-09:00 Opening and Objectives Jolanta Kunikowska,
Ken Herrmann
Cristina Nanni
Carsten Kobe


Thursday, February 3, 2022

Non Hodgkin Lymphoma

Chairpersons: Bruce Cheson, Carsten Kobe

Time Presentation Title Speaker
09:00-09:25 Use of PET in NHL Ann-Segolène Cottereau
09:30-09:55 Biomarkers in NHL Björn Chapuy
10:00-10:25 Radiotherapy in NHL George Mikhaeel
11:00-11:05 Is Ann Arbor dead? Björn Chapuy
11:05-11:25 In Favour Josée M. Zijlstra
11:25-11:45 Against Ullrich Dührsen
12:00-13:00 Consensus on Imaging in NHL Carsten Kobe


Thursday, February 3, 2022

Hodgkin Lymphoma

Chairpersons: Ken Herrmann, Peter Borchmann, Martin Hutchings

Time Presentation Title Speaker
14:00-14:25 Use of PET in HL Martin Hutchings
14:30-14:55 Biomarkers in HL Bruce Cheson
15:00-15:25 Radiotherapy in HL Christian Baues
16:00-16:15 Do we need PET for response assessment? Josée M. Zijlstra
16:15-16:30 Against Peter Borchmann
16:30-16:45 In Favour Stefano Luminari
17:00-18:00 Consensus on Imaging and Therapy in HL Martin Hutchings


Friday, February 4, 2022


Chairpersons: Cristina Nanni, Hermann Einsele, Françoise Kraeber-Bodéré

Time Presentation Title Speaker
09:00-09:25 FDG PET/CT Imaging in Active Myeloma: state of the art and interpretation Cristina Nanni
09:30-09:55 FDG PET/CT for MRD assessment Françoise Kraeber-Bodéré
10:00-10:25 Radiological imaging (MRI, LDCT) Robert Chrzan
11:00-11:20 FDG PET/CT for the evaluation of Plasmacytoma and Smouldering Myeloma Nadia Withofs
11:20-11:40 Beyond FDG Andreas Buck
11:40-12:00 Clinical implications of PET/CT Elena Zamagni
12:00-13:00 Consensus Paula Rodriguez-Otero

Friday, February 4, 2022

New therapies in haematological malignancies

Chairpersons: Jolanta Kunikowska, Pier Luigi Zinzani

Time Presentation Title Speaker
14:00-14:25 CXCR4 Andreas Buck
14:30-14:55 Clinical impact of Zevalin Pier Luigi Zinzani
15:00-15:25 What can be expected from [177Lu]Lu-lilotomab satetraxetan (Betalutin) Wojtek Jurczak
16:00-16:05 Influence of new treatment options on Imaging Pier Luigi Zinzani
16:05-16:25 Imaging PD-1 expression Elisabeth de Vries
16:25-16:45 Influence of Immunotherapies on [18F]FDG Imaging (CAR-T, PD1) Egesta Lopci
17:00-18:00 Consensus Wojtek Jurczak

Saturday, February 5, 2022

New Tools for therapy and diagnosis

Chairpersons: Pier Luigi Zinzani, Andreas Buck, Cristina Nanni

Time Presentation Title Speaker
09:00-09:30 New possible compounds (overview) ([89Zr]Zr-ratezolizumab) Marcel Nijland
09:30-10:00 FAPI Ken Herrmann
10:00-10:20 [18F]fluciclovine Live Eikenes
11:00-11:30 AI and ML in Imaging Cancer Bettina Baeßler
11:30-12:00 Radiomics, AI, ML Irene Buvat
12:00-12:30 Standardization: Pre-equisite for Quantification Ronald Boellaard
12:45-13:00 Future Directions & Closing Remarks Jolanta Kunikowska
Ken Herrmann